Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
ZEGERID
(omeprazole/sodium bicarbonate) Immediate-release Capsules
ZEGERID® (omeprazole/sodium bicarbonate) is a combination of omeprazole, a proton-pump inhibitor, and sodium bicarbonate, an antacid. Omeprazole is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, a racemic mixture of two enantiomers that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is:
 |
Omeprazole is a white to off-white crystalline powder which melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.
ZEGERID is supplied as immediate-release capsules and unit-dose packets as powder for oral suspension. Each capsule contains either 40 mg or 20 mg of omeprazole and 1100 mg of sodium bicarbonate with the following excipients: croscarmellose sodium and sodium stearyl fumarate. Packets of powder for oral suspension contain either 40 mg or 20 mg of omeprazole and 1680 mg of sodium bicarbonate with the following excipients: xylitol, sucrose, sucralose, xanthan gum, and flavorings.
The recommended dosage regimen by indication in adults of ZEGERID for oral suspension and ZEGERID capsules is summarized in Table 1. Only 40 mg ZEGERID for oral suspension is indicated for the reduction of risk of upper GI bleeding in critically ill adult patients and the dosage regimen is summarized in Table 2. All recommended dosages are based upon omeprazole content.
Table 1: Recommended Dosage Regimen of ZEGERID for Oral Suspension and ZEGERID Capsules in Adults by Indication
| Indication | Dosage of ZEGERID for oral suspension or ZEGERID capsules | Treatment Duration |
| Treatment of Active Duodenal Ulcer | 20 mg once daily | 4 weeks1,2 |
| Treatment of Active Benign Gastric Ulcer | 40 mg once daily | 4 to 8 weeks |
| Treatment of Symptomatic GERD | 20 mg once daily | Up to 4 weeks |
| Treatment of EE due to Acid-Mediated GERD | 20 mg once daily | 4 to 8 weeks2 |
| Maintenance of Healing of EE due to Acid-Mediated GERD | 20 mg once daily | Controlled studies do not extend beyond 12 months. |
|
1 Most patients heal within 4 weeks. Some patients may require an additional 4 weeks of therapy. [see Clinical Studies] 2 The efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of ZEGERID may be considered. |
||
Table 2: Recommended Dosage Regimen of 40 mg ZEGERID for Oral Suspension in Adults byIndication
| Indication | Dosage of 40 mg ZEGERID for oral suspension | Treatment Duration |
| Reduction of Risk of Upper GI Bleeding in Critically Ill Patients | 40 mg initially; followed by 40 mg 6 to 8 hours later; and 40 mg once daily thereafter | 14 days |
Oral Administration
Nasogastric (NG) or Orogastric (OG) Tube Administration
ZEGERID is available as:
ZEGERID is supplied as:
| ZEGERID Capsules | |||
| NDC | Strength | Quantity | Description |
| 68012-102-30 | 20 mg omeprazole and 1,100 mg sodium bicarbonate | Bottles of 30 capsules | Opaque, hard gelatin, white capsule, imprinted with the Santarus logo and “20” |
| 68012-104-30 | 40 mg omeprazole and 1,100 mg sodium bicarbonate | Bottles of 30 capsules | Opaque, hard gelatin, colored dark blue and white capsule, imprinted with the Santarus logo and “40” |
| ZEGERID for Oral Suspension | |||
| NDC | Strength | Quantity | Description |
| 68012-052-30 | 20 mg omeprazole and 1,680 mg sodium bicarbonate | Cartons of 30 unit-dose packets | White, flavored powder packaged in unit-dose packets |
| 68012-054-30 | 40 mg omeprazole and 1,680 mg sodium bicarbonate | Cartons of 30 unit-dose packets | White, flavored powder packaged in unit-dose packets. |
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Keep container tightly closed. Protect from light and moisture.
Manufactured for: Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ 08807 USA. Revised: Sep 2019
The following serious adverse reactions are described below and elsewhere in labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ZEGERID has been established, in part, based on oral studies of an oral delayed-release omeprazole product.
In the U.S. clinical trial population of 465 adult patients, the adverse reactions summarized in Table 3 were reported to occur in 1% or more of patients on therapy with omeprazole.
Table 3: Adverse Reactions Occurring in 1% or More of Adult Patients in US Clinical Trials ofOmeprazole Therapy
| Omeprazole % (n = 465) |
Placebo % (n = 64) |
Ranitidine % (n = 195) |
|
| Headache | 7 | 6 | 8 |
| Diarrhea | 3 | 3 | 2 |
| Abdominal Pain | 2 | 3 | 3 |
| Nausea | 2 | 3 | 4 |
| Upper Respiratory Infection (URI) | 2 | 2 | 3 |
| Dizziness | 2 | 0 | 3 |
| Vomiting | 2 | 5 | 2 |
| Rash | 2 | 0 | 0 |
| Constipation | 1 | 0 | 0 |
| Cough | 1 | 0 | 2 |
| Asthenia | 1 | 2 | 2 |
| Back Pain | 1 | 0 | 1 |
Table 4 summarizes the adverse reactions that occurred in 1% or more of omeprazole-treated patients from international double-blind and open-label clinical trials in which 2,631 patients and subjects received omeprazole.
Table 4: Adverse Reactions Occurring in 1% or More of Adult Patients in International Clinical Trials ofOmeprazole Therapy
| Omeprazole % (n = 465) |
Placebo % (n = 64) |
|
| Abdominal Pain | 5.2 | 3.3 |
| Nausea | 4.0 | 6.7 |
| Diarrhea | 3.7 | 2.5 |
| Vomiting | 3.2 | 10.0 |
| Headache | 2.9 | 2.5 |
| Flatulence | 2.7 | 5.8 |
| Acid Regurgitation | 1.9 | 3.3 |
| Constipation | 1.5 | 0.8 |
| Asthenia | 1.3 | 0.8 |
Adverse reactions reported in at least 3% of critically ill adult patients in a clinical trial of 40 mg ZEGERID for oral suspension compared to intravenous cimetidine for up to 14 days are presented in Table 5.
Table 5: Common Adverse Reactions1 by Body System and Preferred Term in a Randomized ControlledTrial of Critically Ill Adult Patients Treated up to 14 Days
| Body System Preferred Term |
ZEGERID 40 mg for oral suspension once daily % (N=178) |
Intravenous Cimetidine 1,200 mg per day % (N=181) |
| Blood and Lymphatic System Disorders | ||
| Anemia NOS | 7.9 | 7.7 |
| Anemia NOS Aggravated | 2.2 | 3.9 |
| Thrombocytopenia | 10.1 | 6.1 |
| Cardiac Disorders | ||
| Atrial Fibrillation | 6.2 | 3.9 |
| Bradycardia NOS | 3.9 | 2.8 |
| Supraventricular Tachycardia | 3.4 | 1.1 |
| Tachycardia NOS | 3.4 | 3.3 |
| Ventricular Tachycardia | 4.5 | 3.3 |
| Gastrointestinal Disorders2 | ||
| Constipation | 4.5 | 4.4 |
| Diarrhea NOS | 3.9 | 8.3 |
| Gastric Hypomotility | 1.7 | 3.3 |
| General Disorders and Administration Site Conditions | ||
| Hyperpyrexia | 4.5 | 1.7 |
| Edema NOS | 2.8 | 6.1 |
| Pyrexia | 20.2 | 16.0 |
| Infections and Infestations | ||
| Candidal Infection NOS | 1.7 | 3.9 |
| Oral Candidiasis | 3.9 | 0.6 |
| Sepsis NOS | 5.1 | 5.0 |
| Urinary Tract Infection | 2.2 | 3.3 |
| Investigations | ||
| Liver Function Tests NOS Abnormal | 1.7 | 3.3 |
| Metabolism and Nutrition Disorders | ||
| Fluid Overload | 5.1 | 7.7 |
| Hyperglycemia NOS | 10.7 | 11.6 |
| Hyperkalemia | 2.2 | 3.3 |
| Hypernatremia | 1.7 | 5.0 |
| Hypocalcemia | 6.2 | 5.5 |
| Hypoglycemia NOS | 3.4 | 4.4 |
| Hypokalemia | 12.4 | 13.3 |
| Hypomagnesemia | 10.1 | 9.9 |
| Hyponatremia | 3.9 | 2.8 |
| Hypophosphatemia | 6.2 | 3.9 |
| Psychiatric Disorders | ||
| Agitation | 3.4 | 8.8 |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Acute Respiratory Distress Syndrome | 3.4 | 3.9 |
| Nosocomial Pneumonia | 11.2 | 9.4 |
| Pneumothorax NOS | 0.6 | 4.4 |
| Respiratory Failure | 1.7 | 3.3 |
| Skin and Subcutaneous Tissue Disorders | ||
| Decubitus Ulcer | 3.4 | 2.8 |
| Rash NOS | 5.6 | 6.1 |
| Vascular Disorders | ||
| Hypertension NOS | 7.9 | 3.3 |
| Hypotension NOS | 9.6 | 6.6 |
|
NOS = not otherwise specified 1 reported in at least 3% of patients in either treatment group. 2 In this trial, clinically significant upper gastrointestinal bleeding was considered a serious adverse reaction, but it is not included in this table. |
||
The following adverse reactions have been identified during post-approval use of omeprazole and sodium bicarbonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole: Hypersensitivity reactions, including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria (see also Skin below), fever, pain, fatigue, malaise, and systemic lupus erythematosus.
Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitation, elevated blood pressure, and peripheral edema.
Gastrointestinal: Pancreatitis (some fatal), anorexia, irritable colon, flatulence, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, dry mouth, stomatitis, abdominal swelling and fundic gland polyps. Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term treatment with omeprazole. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.
Hepatic: Mild and, rarely, marked elevations of liver function tests [ALT (SGPT), AST (SGOT), γ-glutamyl transpeptidase, alkaline phosphatase, and bilirubin (jaundice)]. In rare instances, overt liver disease has occurred, including hepatocellular, cholestatic, or mixed hepatitis, liver necrosis (some fatal), hepatic failure (some fatal), and hepatic encephalopathy.
Infections and Infestations: Clostridium difficile-associated diarrhea.
Metabolism and Nutritional Disorders: Hyponatremia, hypoglycemia, hypomagnesemia, and weight gain.
Musculoskeletal: Muscle cramps, myalgia, muscle weakness, joint pain, bone fracture, and leg pain.
Nervous System/Psychiatric: Psychic disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, tremors, apathy, somnolence, anxiety, dream abnormalities; vertigo; paresthesia; and hemifacial dysesthesia.
Respiratory: Epistaxis, pharyngeal pain.
Skin: Severe generalized skin reactions including toxic epidermal necrolysis (TEN; some fatal), Stevens-Johnson syndrome, cutaneous lupus erythematosus and erythema multiforme (some severe); purpura and/or petechiae (some with rechallenge); skin inflammation, urticaria, angioedema, pruritus, photosensitivity, alopecia, dry skin, and hyperhidrosis.
Special Senses: Tinnitus, taste perversion.
Ocular: Blurred vision, ocular irritation, dry eye syndrome, optic atrophy, anterior ischemic optic neuropathy, optic neuritis, and double vision.
Urogenital: Interstitial nephritis (some with positive rechallenge), urinary tract infection, microscopic pyuria, urinary frequency, elevated serum creatinine, proteinuria, hematuria, glycosuria, testicular pain, and gynecomastia.
Hematologic: Rare instances of pancytopenia, agranulocytosis (some fatal), thrombocytopenia, neutropenia, leukopenia, anemia, leukocytosis, and hemolytic anemia have been reported.
metabolic alkalosis, seizures, and tetany.
Tables 6 and 7 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them.
Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 6: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics
| Antiretrovirals | |
| Clinical Impact: | The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
|
| Intervention: | Rilpivirine-containing products: Concomitant use with ZEGERID is contraindicated [see CONTRAINDICATIONS]. |
| Atazanavir: Avoid concomitant use with ZEGERID. See prescribing information for atazanavir for dosing information. | |
| Nelfinavir: Avoid concomitant use with ZEGERID. See prescribing information for nelfinavir. | |
| Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. | |
| Other antiretrovirals: See prescribing information for specific antiretroviral drugs. | |
| Warfarin | |
| Clinical Impact: | Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. |
| Intervention: | Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. |
| Methotrexate | |
| Clinical Impact: | Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted [see WARNINGS AND PRECAUTIONS]. |
| Intervention: | A temporary withdrawal of ZEGERID may be considered in some patients receiving high-dose methotrexate. |
| CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) | |
| Clopidogrel | |
| Clinical Impact: | Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see CLINICAL PHARMACOLOGY]. |
| There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. | |
| Intervention: | Avoid concomitant use with ZEGERID. Consider use of alternative anti-platelet therapy [see WARNINGS AND PRECAUTIONS]. |
| Citalopram | |
| Clinical Impact: | Increased exposure of citalopram leading to an increased risk of QT prolongation [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram. |
| Cilostazol | |
| Clinical Impact: | Increased exposure of one of the active metabolites of cilostazol (3,4-dihydrocilostazol) [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol. |
| Phenytoin | |
| Clinical Impact: | Potential for increased exposure of phenytoin. |
| Intervention: | Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. |
| Diazepam | |
| Clinical Impact: | Increased exposure of diazepam [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Monitor patients for increased sedation and reduce the dose of diazepam as needed. |
| Digoxin | |
| Clinical Impact: | Potential for increased exposure of digoxin [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information. |
| Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) | |
| Clinical Impact: | Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. |
| Intervention: | Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving ZEGERID and MMF. Use ZEGERID with caution in transplant patients receiving MMF [see CLINICAL PHARMACOLOGY]. |
| See the prescribing information for other drugs dependent on gastric pH for absorption. | |
| Tacrolimus | |
| Clinical Impact: | Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. |
| Intervention: | Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. |
| Interactions with Investigations of Neuroendocrine Tumors | |
| Clinical Impact: | Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY]. |
| Intervention: | Temporarily stop PRILOSEC treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. |
| Interaction with Secretin Stimulation Test | |
| Clinical Impact: | Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. |
| Intervention: | Temporarily stop ZEGERID treatment at least 14 days before assessing to allow gastrin levels to return to baseline [see CLINICAL PHARMACOLOGY]. |
| False Positive Urine Tests for THC | |
| Clinical Impact: | There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. |
| Intervention: | An alternative confirmatory method should be considered to verify positive results. |
| Other | |
| Clinical Impact: | There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). |
| Intervention: | Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with ZEGERID. |
Table 7: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with OtherDrugs
| CYP2C19 or CYP3A4 Inducers | |
| Clinical Impact: | Decreased exposure of omeprazole when used concomitantly with strong inducers [see CLINICAL PHARMACOLOGY]. |
| Intervention: | St. John’s Wort, rifampin: Avoid concomitant use with ZEGERID [see WARNINGS AND PRECAUTIONS]. |
| Ritonavir-containing products: see prescribing information for specific drugs. | |
| CYP2C19 or CYP3A4 Inhibitors | |
| Clinical Impact: | Increased exposure of omeprazole [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Voriconazole: Dosage adjustment of ZEGERID is not required. |
Included as part of the "PRECAUTIONS" Section
In adults, symptomatic response to therapy with ZEGERID does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a proton pump inhibitor (PPI). In older patients, also consider an endoscopy.
Acute interstitial nephritis has been observed in patients taking PPIs including ZEGERID. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue ZEGERID if acute interstitial nephritis develops. [see CONTRAINDICATIONS]
Each 20 mg and 40 mg ZEGERID capsule contains 1,100 mg (13 mEq) of sodium bicarbonate. The total content of sodium in each capsule is 304 mg.
Each 20 mg and 40 mg packet of ZEGERID for oral suspension contains 1,680 mg (20 mEq) of sodium bicarbonate. The total content of sodium in each packet is 460 mg.
Chronic administration of bicarbonate with calcium or milk can cause milk-alkali syndrome. Chronic use of sodium bicarbonate may lead to systemic alkalosis, and increased sodium intake can produce edema and weight gain.
The sodium content of ZEGERID products should be taken into consideration when administering to patients on a sodium-restricted diet or those at risk for developing congestive heart failure.
Avoid ZEGERID in patients with Bartter’s syndrome, hypokalemia, hypocalcemia, and problems with acid-base balance.
Published observational studies suggest that PPI therapy like ZEGERID may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. [see ADVERSE REACTIONS]
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines. [see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS]
Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including omeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematous cases were CLE.
The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement.
Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs. PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported.
Avoid administration of PPIs for longer than medically indicated. If signs or symptoms consistent with CLE or SLE are noted in patients receiving ZEGERID, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.
Avoid concomitant use of ZEGERID with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Concomitant use of clopidogrel with 80 mg omeprazole reduces the pharmacological activity of clopidogrel, even when administered 12 hours apart. When using ZEGERID, consider alternative antiplatelet therapy. [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY]
Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo-or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed in patients treated with ZEGERID.
Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.
For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically. [see ADVERSE REACTIONS]
Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s wort or rifampin) can substantially decrease omeprazole concentrations [see DRUG INTERACTIONS]. Avoid concomitant use of ZEGERID with St. John’s wort or rifampin.
Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop ZEGERID treatment for at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. [see DRUG INTERACTIONS]
Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients. [see DRUG INTERACTIONS]
PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially beyond one year. Most PPIs users who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of PPI therapy appropriate to the condition being treated.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Advise the patient to call their healthcare provider immediately if they experience signs and/or symptoms associated with acute interstitial nephritis [see WARNINGS AND PRECAUTIONS].
Inform patients on a sodium-restricted diet or patients at risk of developing congestive heart failure of the sodium content of ZEGERID capsules (304 mg per capsule) and ZEGERID for oral suspension (460 mg per packet).
Advise patients that:
If any of these occur, instruct patients to contact their healthcare provider [see WARNINGS AND PRECAUTIONS].
Advise the patient to immediately call their healthcare provider if they experience diarrhea that does not improve [see WARNINGS AND PRECAUTIONS].
Advise the patient to report any fractures, especially of the hip, wrist or spine, to their healthcare provider [see WARNINGS AND PRECAUTIONS].
Advise the patient to immediately call their healthcare provider for any new or worsening of symptoms associated with cutaneous or systemic lupus erythematosus [see WARNINGS AND PRECAUTIONS].
Advise the patient to report any clinical symptoms that may be associated with cyanocobalamin deficiency to their healthcare provider if they have been receiving ZEGERID for longer than 3 years [see WARNINGS AND PRECAUTIONS].
Advise the patient to report any clinical symptoms that may be associated with hypomagnesemia to their healthcare provider, if they have been receiving ZEGERID for at least 3 months [see WARNINGS AND PRECAUTIONS].
Advise patients to report to their healthcare provider if they start treatment with rilpivirine-containing products, clopidogrel, St. John’s wort or rifampin, or if they take high-dose methotrexate [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].
Instruct patients that:
In two 24-month carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44.0 and 140.8 mg/kg/day (approximately 0.4 to 34.2 times the human dose of 40 mg/day on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (approximately 3.36 times the human dose of 40 mg/day on a body surface area basis) for one year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell hyperplasia was observed at the end of one year (94% treated versus 10% controls). By the second year the difference between treated and control rats was much smaller (46% versus 26%) but still showed more hyperplasia in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for two years. For this strain of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. In a 52-week toxicity study in Sprague Dawley rats, brain astrocytomas were found in a small number of males that received omeprazole at dose levels of 0.4, 2, and 16 mg/kg/day (about 0.1 to 3.9 times the human dose of 40 mg/day on a body surface area basis). No astrocytomas were observed in female rats in this study. In a 2-year carcinogenicity study in Sprague Dawley rats, no astrocytomas were found in males and females at the high dose of 140.8 mg/kg/day (about 34 times the human dose of 40 mg/day on a body surface area basis). A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive. A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.
Omeprazole was positive for clastogenic effects in an in vitro human lymphocyte chromosomal aberration assay, in one of two in vivo mouse micronucleus tests, and in an in vivo bone marrow cell chromosomal aberration assay. Omeprazole was negative in the in vitro Ames test, an in vitro mouse lymphoma cell forward mutation assay and an in vivo rat liver DNA damage assay.
In a 24-month carcinogenicity studies in rats, a dose-related significant increase in gastric carcinoid tumors and ECL cell hyperplasia was observed in both male and female animals. Carcinoid tumors have also been observed in rats subjected to fundectomy or long-term treatment with other PPIs or high doses of H2-receptor antagonists.
Omeprazole at oral doses up to 138 mg/kg/day (about 33.6 times the human dose of 40 mg/day on a body surface area basis) was found to have no effect on the fertility and general reproductive performance in rats.
There are no adequate and well-controlled studies with ZEGERID in pregnant women. ZEGERID contains omeprazole and sodium bicarbonate.
Omeprazole
There are no adequate and well-controlled studies with omeprazole in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. Reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34 times an oral human dose of 40 mg (based on a body surface area for a 60 kg person).
Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with doses about 68 times and 42 times, respectively, an oral human dose of 40 mg esomeprazole or 40 mg omeprazole (based on body surface area for a 60 kg person). Changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole. When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age (see Data).
Sodium Bicarbonate
Available data with sodium bicarbonate use in pregnant women are insufficient to identify a drug associated risk of major birth defects or miscarriage. Published animal studies report that sodium bicarbonate administered to rats, mice or rabbits during pregnancy did not cause adverse developmental effects in offspring.
The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Human Data
There are no adequate and well-controlled studies with ZEGERID in pregnant women. Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H2-receptor antagonists or other controls.
A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Register, covering approximately 99% of pregnancies, from 1995-99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. The number of infants exposed in utero to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population. The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population.
A population-based retrospective cohort study covering all live births in Denmark from 1996-2009 reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837,317 live births whose mothers did not use any PPI. The overall rate of birth defects in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any PPI during the first trimester.
A retrospective cohort study reported on 689 pregnant women exposed to either H2-blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester. The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H2-blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively.
A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non-teratogens, and 2.8% in disease-paired controls. Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight were similar among the groups.
Several studies have reported no apparent adverse short-term effects on the infant when single-dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.
Omeprazole
Reproductive studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at doses up to 69.1 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis) during organogenesis did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 3.4 to 34 times an oral human dose of 40 mg on a body surface area basis) administered during organogenesis produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 3.4 to 34 times an oral human dose of 40 mg on a body surface area basis), administered prior to mating through the lactation period.
Esomeprazole
The data described below was generated from studies using esomeprazole, an enantiomer of omeprazole. The animal to human dose multiples are based on the assumption of equal systemic exposure to esomeprazole in humans following oral administration of either 40 mg esomeprazole or 40 mg omeprazole.
No effects on embryo-fetal development were observed in reproduction studies with esomeprazole magnesium in rats at oral doses up to 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 42 times an oral human dose of 40 mg of esomeprazole or 40 mg omeprazole on a body surface area basis) administered during organogenesis.
A pre-and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development were performed with esomeprazole magnesium at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg of esomeprazole or 40 mg omeprazole on a body surface area basis). Neonatal/early postnatal (birth to weaning) survival was decreased at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). Body weight and body weight gain were reduced and neurobehavioral or general developmental delays in the immediate post-weaning timeframe were evident at doses equal to or greater than 69 mg/kg/day (about 17 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). In addition, decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate and minimal to mild bone marrow hypocellularity were noted at doses of esomeprazole magnesium equal to or greater than 14 mg/kg/day (about 3.4 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). Physeal dysplasia in the femur was observed in offspring of rats treated with oral doses of esomeprazole magnesium at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis).
Effects on maternal bone were observed in pregnant and lactating rats in a pre-and postnatal toxicity study when esomeprazole magnesium was administered at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). When rats were dosed from gestational Day 7 through weaning on postnatal Day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses of esomeprazole magnesium equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis).
A pre-and postnatal development study in rats with esomeprazole strontium (using equimolar doses compared to esomeprazole magnesium study) produced similar results in dams and pups as described above.
A follow up developmental toxicity study in rats with further time points to evaluate pup bone development from postnatal day 2 to adulthood was performed with esomeprazole magnesium at oral doses of 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) where esomeprazole administration was from either gestational day 7 or gestational day 16 until parturition. When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age.
Available data from the published literature suggest both components of ZEGERID, omeprazole and sodium bicarbonate, are present in human milk. There are no clinical data on the effects of omeprazole or sodium bicarbonate on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEGERID and any potential adverse effects on the breastfed infant from ZEGERID or from the underlying maternal condition.
Safety and effectiveness of ZEGERID have not been established in pediatric patients.
Esomeprazole, an enantiomer of omeprazole, was shown to decrease body weight, body weight gain, femur weight, femur length, and overall growth at oral doses about 34 to 68 times a daily human dose of 40 mg esomeprazole or 40 mg omeprazole based on body surface area in a juvenile rat toxicity study. The animal to human dose multiples are based on the assumption of equal systemic exposure to esomeprazole in humans following oral administration of either 40 mg esomeprazole or 40 mg omeprazole.
A 28-day toxicity study with a 14-day recovery phase was conducted in juvenile rats with esomeprazole magnesium at doses of 70 to 280 mg/kg/day (about 17 to 68 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). An increase in the number of deaths at the high dose of 280 mg/kg/day was observed when juvenile rats were administered esomeprazole magnesium from postnatal day 7 through postnatal day 35. In addition, doses equal to or greater than 140 mg/kg/day (about 34 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis), produced treatment-related decreases in body weight (approximately 14%) and body weight gain, decreases in femur weight and femur length, and affected overall growth. Comparable findings described above have also been observed in this study with another esomeprazole salt, esomeprazole strontium, at equimolar doses of esomeprazole.
Omeprazole was administered to over 2000 elderly individuals (≥65 years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
Pharmacokinetic studies with buffered omeprazole have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects). The plasma half-life averaged one hour, about twice that in nonelderly, healthy subjects taking ZEGERID. However, no dosage adjustment is necessary in the elderly. [see CLINICAL PHARMACOLOGY]
In patients with hepatic impairment (Child-Pugh Class A, B, or C) exposure to omeprazole substantially increased compared to healthy subjects. Avoid use of ZEGERID in patients with hepatic impairment for maintenance of healing of erosive esophagitis [see CLINICAL PHARMACOLOGY]
In studies of healthy subjects, Asians had approximately a four-fold higher exposure than Caucasians. Avoid use of ZEGERID in Asian patients for maintenance of healing of erosive esophagitis. [see CLINICAL PHARMACOLOGY]
If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.
Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in clinical experience with the recommended dosage [see ADVERSE REACTIONS]. Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.
Overdosage of sodium bicarbonate can cause electrolyte abnormalities (hypocalcemia, hypokalemia, hypernatremia), metabolic alkalosis, and seizures. Institute supportive care and correct electrolyte abnormalities.
Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
Results from a pharmacokinetic/pharmacodynamic (PK/PD) study of the antisecretory effect of repeated once-daily dosing of 40 mg and 20 mg of ZEGERID for oral suspension in healthy subjects are shown in Table 8 below.
Table 8: Effect of ZEGERID for Oral Suspension on Intragastric pH, Day 7
| Parameter | Once Daily Dosage of ZEGERID for Oral Suspension | |
| 40 mg omeprazole and 1,680 mg sodium bicarbonate (n = 24) |
20 mg omeprazole and 1,680 mg sodium bicarbonate (n = 28) |
|
| % Decrease from Baseline for Integrated Gastric Acidity (mmol•hr/L) | 84% | 82% |
| Coefficient of Variation | 20% | 24% |
| % Time Gastric pH > 4 1 (Hours)1 | 77% (18.6 h) | 51% (12.2 h) |
| Coefficient of Variation | 27% | 43% |
| Median pH | 5.2 | 4.2 |
| Coefficient of Variation | 17% | 37% |
| Note: Values represent medians. All parameters were measured over a 24-hour period. | ||
| 1. P < 0.05 20 mgvs. 40 mg | ||
Results from a separate PK/PD study of antisecretory effect on repeated once-daily dosing of 40 mg/1,100 mg and 20 mg/1,100 mg of ZEGERID capsules in healthy subjects show similar effects in general on the above three PD parameters as those for ZEGERID for oral suspension 40 mg/1,680 mg and 20 mg/1,680 mg, respectively.
The antisecretory effect lasts longer than would be expected from the very short (1 hour) plasma half-life, apparently due to irreversible binding to the parietal H+/K+ ATPase enzyme.
Human gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. These studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.
In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H2-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6-fold vs. 1.1-to 1.8-fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.
Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors [see WARNINGS AND PRECAUTIONS].
Systemic effects of omeprazole in the central nervous system (CNS), cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single intravenous dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans. However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased.
As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva. All changes resolved within three days of stopping treatment.
The course of Barrett’s esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months. No clinically significant impact on Barrett’s mucosa by antisecretory therapy was observed. Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett’s mucosa was not achieved. No significant difference was observed between treatment groups in development of dysplasia in Barrett’s mucosa, and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter.
Tables 9 and 10 show the systemic exposures and the time reach peak concentration (Tmax) of omeprazole in healthy subjects following administration of ZEGERID capsules and oral suspension, respectively, on an empty stomach one hour prior to a meal.
Table 9: Arithmetic Mean (CV%) of the Systemic Exposures (Cmax, AUC) and Tmax of Omeprazole after a Single Oral Dose and Multiple Once Daily Doses of ZEGERID Capsules
| 20 mg ZEGERID capsules | 40 mg ZEGERID capsules | |||||
| Day 1 | Day 7 | % Change (Day 7/Day 1) | Day 1 | Day 7 | % Change (Day 7/Day 1) | |
| Cmax (ng/mL) | 498.1 (50.9) | 679.8 (44.0) | 36 | 1154 (53.0) | 1526 (48.7) | 32 |
| Tmax (hr) [min – max] | 0.61 [0.25-1.5] |
0.82 [0.25-1.5] |
n.a. | 0.56 [0.25-1.5] |
0.97 [0.25-3.5] |
n.a. |
| AUC0-inf * (ng•hr/mL) | 509.7 (60.5) | 1029 (67.9) | 102 | 1882 (120) | 3866 (83.3) | 105 |
| n.a.: not applicable * AUC0-24h was used on Day 7 |
||||||
Table 10: Arithmetic Mean (CV%) of the Systemic Exposures (Cmax, AUC) and Tmax of Omeprazole after a Single Oral Dose and Multiple Once Daily Doses of ZEGERID Oral Suspension.
| 20 mg ZEGERID oral suspension | 40 mg ZEGERID oral suspension | |||||
| Day 1 | Day 7 | % Change (Day 7/Day 1) | Day 1 | Day 7 | % Change (Day 7/Day 1) | |
| Cmax (ng/mL) | 671.9 (43.8) | 902.2 (39.6) | 34 | 1412 (43.7) | 1954 (33.5) | 38 |
| Tmax (hr) [min – max] | 0.50 [0.17-1.5] | 0.47 [0.17-1.0] | n.a. | 0.44 [0.17-1.0] | 0.58 [0.25-1.0] | n.a. |
| AUC0-inf * (ng•hr/mL) | 825.4 (71.9) | 1449 (61.7) | 76 | 2228 (107) | 4692 (60.5) | 111 |
| n.a.: not applicable * AUC0-24h was used on Day 7 |
||||||
Following single or repeated once-daily dosing, peak plasma concentrations (Cmax) of omeprazole from ZEGERID were approximately proportional from 20 to 40 mg doses. A greater than dose proportional increase in mean steady-state AUC (more than three-fold increase on Day 7) was observed when doubling the dose to 40 mg. The bioavailability of omeprazole from ZEGERID increases upon repeated administration. The percent changes in Cmax and AUC between steady-state (Day 7) and single dose (Day 1) indicate omeprazole is a time-dependent autoinhibitor of CYP2C19.
When ZEGERID for oral suspension 40 mg was administered in a two-dose loading regimen, the omeprazole AUC(0-inf) (ng•hr/mL) was 1665 after Dose 1 and 3356 after Dose 2, while Tmax was approximately 30 minutes for both Dose 1 and Dose 2.
When ZEGERID for oral suspension 40 mg or ZEGERID capsule 40 mg is administered one hour after a meal, the omeprazole AUC is reduced by approximately 27% and 22%, respectively, relative to administration one hour prior to a meal [see DOSAGE AND ADMINISTRATION].
Omeprazole is bound to plasma proteins. Protein binding is approximately 95%.
Metabolism
Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The major part of its metabolism is dependent on the polymorphically expressed CYP2C19 [see Pharmacogenomics], responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone.
The mean plasma omeprazole half-life following administration of ZEGERID capsule or ZEGERID oral suspension in healthy subjects is approximately 1 hour (range 0.4 to 4.2 hours), and the total body clearance is 500 to 600 mL/min.
Excretion
Following single-dose oral administration of a buffered solution of omeprazole, the majority of the dose (about 77%) is eliminated in urine as at least six metabolites. Two metabolites have been identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces. This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma – the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole. These metabolites have very little or no antisecretory activity.
The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased. Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly subjects versus 58% in young subjects given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole, and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects), and its plasma half-life averaged one hour, similar to that of young healthy subjects.
There are no known differences in the absorption or excretion of omeprazole between males and females.
Patients with Renal Impairment
In patients with chronic renal impairment (creatinine clearance between 10 and 62 mL/min/1.73 m2), the disposition of omeprazole was very similar to that in healthy subjects, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. This increase in bioavailability is not considered to be clinically meaningful.
Patients with Hepatic Impairment
In patients with chronic hepatic disease classified as Child-Pugh Class A (n=3), B (n=4) and C (n=1), the bioavailability of omeprazole increased to approximately 100% compared to healthy subjects, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared to the in healthy subjects of 0.5 to 1 hour. Plasma clearance averaged 70 mL/min, compared to a value of 500 to 600 mL/min in healthy subjects [see Use In Specific Populations].
Omeprazole is a time-dependent inhibitor of CYP2C19 and can increase the systemic exposure of co-administered drugs that are CYP2C19 substrates. In addition, administration of omeprazole increases intragastric pH and can alter the systemic exposure of certain drugs that exhibit pH-dependent solubility [see DRUG INTERACTIONS].
For some antiretroviral drugs, such as rilpivirine, atazanavir and nelfinavir, decreased serum concentrations have been reported when given together with omeprazole [see DRUG INTERACTIONS].
Rilpivirine
Following multiple doses of rilpivirine (150 mg, daily) and omeprazole (20 mg, daily), AUC was decreased by 40%, Cmax by 40%, and Cmin by 33% for rilpivirine.
Nelfinavir
Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8.
Atazanavir
Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hours before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.
Saquinavir
Following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15.
AUC was increased by 82%, Cmax by 75%, and Cmin by 106%. The mechanism behind this interaction is not fully elucidated. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with PRILOSEC.
In a crossover clinical study, 72 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as clopidogrel) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when clopidogrel and omeprazole were administered together.
Results from another crossover study in healthy subjects showed a similar pharmacokinetic interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole 80 mg daily when coadministered for 30 days. Exposure to the active metabolite of clopidogrel was reduced by 41% to 46% over this time period.
In another study, 72 healthy subjects were given the same doses of clopidogrel and 80 mg omeprazole, but the drugs were administered 12 hours apart; the results were similar, indicating that administering clopidogrel and omeprazole at different times does not prevent their interaction [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS].
Administration of omeprazole 20 mg twice daily for 4 days and a single 1000 mg dose of MMF approximately one hour after the last dose of omeprazole to 12 healthy subjects in a crossover study resulted in a 52% reduction in the Cmax and 23% reduction in the AUC of MPA [see DRUG INTERACTIONS].
Omeprazole acts as an inhibitor of CYP2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased Cmax and AUC of cilostazol by 18% and 26% respectively. The Cmax and AUC of one of the active metabolites, 3,4-dihydro-cilostazol, which has 4-7 times the activity of cilostazol, were increased by 29% and 69%, respectively. Co-administration of cilostazol with omeprazole is expected to increase concentrations of cilostazol and the above mentioned active metabolite [see DRUG INTERACTIONS].
Concomitant administration of omeprazole 20 mg once daily and diazepam 0.1 mg/kg given intravenously resulted in 27% decrease in clearance and 36% increase in diazepam half-life [see DRUG INTERACTIONS].
Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) [see DRUG INTERACTIONS].
Voriconazole
Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. When voriconazole (400 mg every 12 hours for one day, followed by 200 mg once daily for 6 days) was given with omeprazole (40 mg once daily for 7 days) to healthy subjects, the steady-state Cmax and AUC0-24 of omeprazole significantly increased: an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4), respectively, as compared to when omeprazole was given without voriconazole [see DRUG INTERACTIONS].
CYP2C19, a polymorphic enzyme, is involved in the metabolism of omeprazole. The CYP2C19*1 allele is fully functional while the CYP2C19*2 and *3 alleles are nonfunctional. There are other alleles associated with no or reduced enzymatic function. Patients carrying two fully functional alleles are extensive metabolizers and those carrying two loss-of-function alleles are poor metabolizers. In extensive metabolizers, omeprazole is primarily metabolized by CYP2C19. The systemic exposure to omeprazole varies with a patient’s metabolism status: poor metabolizers > intermediate metabolizers > extensive metabolizers. Approximately 3% of Caucasians and 15 to 20% of Asians are CYP2C19 poor metabolizers.
In pharmacokinetic studies of single 20 mg omeprazole dose, the AUC of omeprazole in Asian subjects was approximately four-fold of that in Caucasians [see Use In Specific Populations].
The effectiveness of ZEGERID has been established, in part, based on studies of an oral delayed-release omeprazole product for the treatment of active duodenal ulcer, active benign gastric ulcer, symptomatic GERD, EE due to acid-mediated GERD, and maintenance of healing of EE due to acid-mediated GERD [see Active Duodenal Ulcer, Active Benign Gastric Ulcer, Symptomatic GERD, EE Due To Acid-Mediated GERD, Maintenance Of Healing Of EE Due To Acid-Mediated GERD].
ZEGERID for oral suspension was studied for the reduction of risk of upper GI bleeding in critically ill adult patients [see Reduction Of Risk Of Upper Gastrointestinal Bleeding In Critically Ill Patients].
In a multicenter, double-blind, placebo-controlled study of 147 patients with endoscopically documented duodenal ulcer, the percentage of patients healed (per protocol) at 2 and 4 weeks was significantly higher with omeprazole delayed-release capsules 20 mg once a day than with placebo (p ≤ 0.01). (See Table 11.)
Table 11: Treatment of Active Duodenal Ulcer
| % of Patients Healed | ||
| Omeprazole 20 mg a.m. (n = 99) |
Placebo a.m. (n = 48) |
|
| Week 2 | 411 | 13 |
| Week 4 | 751 | 27 |
| 1. (p ≤ 0.01) | ||
Complete daytime and nighttime pain relief occurred significantly faster (p ≤ 0.01) in patients treated with omeprazole 20 mg than in patients treated with placebo. At the end of the study, significantly more patients who had received omeprazole had complete relief of daytime pain (p ≤ 0.05) and nighttime pain (p ≤ 0.01).
In a multicenter, double-blind study of 293 patients with endoscopically documented duodenal ulcer, the percentage of patients healed (per protocol) at 4 weeks was significantly higher with omeprazole 20 mg once a day than with ranitidine 150 mg twice daily (p < 0.01). (See Table 12.)
Table 12: Treatment of Active Duodenal Ulcer % of Patients Healed
| Omeprazole 20 mg a.m. (n = 145) |
Ranitidine 150 mg twice daily (n = 148) |
|
| Week 2 | 42 | 34 |
| Week 4 | 821 | 63 |
| 1. (p < 0.01) | ||
Healing occurred significantly faster in patients treated with omeprazole than in those treated with ranitidine 150 mg twice daily (p < 0.01).
In a foreign multinational randomized, double-blind study of 105 patients with endoscopically documented duodenal ulcer, 40 mg and 20 mg of omeprazole were compared to 150 mg twice daily of ranitidine at 2, 4 and 8 weeks. At 2 and 4 weeks both doses of omeprazole were statistically superior (per protocol) to ranitidine, but 40 mg was not superior to 20 mg of omeprazole, and at 8 weeks there was no significant difference between any of the active drugs. (See Table 13.)
Table 13: Treatment of Active Duodenal Ulcer % of Patients Healed
| Omeprazole | Ranitidine 150 mg twice daily (n = 35) |
||
| 40 mg (n = 36) |
20 mg (n = 34) |
||
| Week 2 | 831 | 831 | 53 |
| Week 4 | 1001 | 971 | 82 |
| Week 8 | 100 | 100 | 94 |
| 1. (p ≤ 0.01) | |||
In a U.S. multicenter, double-blind study of omeprazole 40 mg once a day, 20 mg once a day, and placebo in 520 patients with endoscopically diagnosed gastric ulcer, the following results were obtained. (See Table 14.)
Table 14: Treatment of Gastric Ulcer % of Patients Healed (All Patients Treated)
| Omeprazole 40 mg once daily (n = 214) |
Omeprazole 20 mg once daily (n = 202) |
Placebo (n = 104) |
|
| Week 4 | 55.61 | 47.51 | 30.8 |
| Week 8 | 82.71,2 | 74.81 | 48.1 |
| 1. (p < 0.01) omeprazole 40 mg or 20 mg versus placebo 2. (p < 0.05) omeprazole 40 mg versus 20 mg |
|||
For the stratified groups of patients with ulcer size less than or equal to 1 cm, no difference in healing rates between 40 mg and 20 mg was detected at either 4 or 8 weeks. For patients with ulcer size greater than 1 cm, 40 mg was significantly more effective than 20 mg at 8 weeks.
In a foreign, multinational, double-blind study of 602 patients with endoscopically diagnosed gastric ulcer, omeprazole 40 mg once a day, 20 mg once a day, and ranitidine 150 mg twice a day were evaluated. (See Table 15.)
Table 15: Treatment of Gastric Ulcer % of Patients Healed (All Patients Treated)
| Omeprazole 40 mg once daily (n = 187) |
Omeprazole 20 mg once daily (n = 200) |
Ranitidine 150 mg twice daily (n = 199) |
|
| Week 4 | 78.11,2 | 63.5 | 56.3 |
| Week 8 | 91.41,2 | 81.5 | 78.4 |
| 1. (p < 0.01) omeprazole 40 mg versus ranitidine 2. (p < 0.01) omeprazole 40 mg versus 20 mg |
|||
A placebo-controlled study was conducted in Scandinavia to compare the efficacy of omeprazole 20 mg or 10 mg once daily for up to 4 weeks in the treatment of heartburn and other symptoms in GERD patients without EE. Results are shown in Table 16.
Table 16: % Successful Symptomatic Outcome1
| Omeprazole 20 mg a.m. |
Omeprazole 10 mg a.m. |
Placebo a.m. |
|
| All Patients | 462,3 (n = 205) |
313 (n = 199) |
13 (n = 105) |
| Patients with Confirmed GERD | 562,3 (n = 115) |
363 (n = 109) |
14 (n = 59) |
| 1. Defined as complete resolution of heartburn 2. (p < 0.005) versus 10 mg 3. (p < 0.005) versus placebo |
|||
In a U.S. multicenter, double-blind, placebo-controlled study of 40 mg or 20 mg of omeprazole delayed-release capsules in patients with symptoms of GERD and endoscopically diagnosed erosive esophagitis of grade 2 or above, the percentage healing rates (per protocol) were as shown in Table 17.
Table 17: % Patients Healed
| Omeprazole 40 mg (n = 87) |
Omeprazole 20 mg (n = 83) |
Placebo (n = 43) |
|
| Week 4 | 451 | 391 | 7 |
| Week 8 | 751 | 741 | 14 |
| 1. (p < 0.01) omeprazole versus placebo. | |||
In this study, the 40 mg dose was not superior to the 20 mg dose of omeprazole in the percentage healing rate. Other controlled clinical trials have also shown that omeprazole is effective in severe GERD. In comparisons with histamine H2-receptor antagonists in patients with erosive esophagitis, grade 2 or above, omeprazole in a dose of 20 mg was significantly more effective than the active controls. Complete daytime and nighttime heartburn relief occurred significantly faster (p < 0.01) in patients treated with omeprazole than in those taking placebo or histamine H2-receptor antagonists.
In this and five other controlled GERD studies, significantly more patients taking 20 mg omeprazole (84%) reported complete relief of GERD symptoms than patients receiving placebo (12%).
In a U.S. double-blind, randomized, multicenter, placebo-controlled study; two dose regimens of omeprazole were studied in patients with endoscopically confirmed healed esophagitis. Results to determine maintenance of healing of erosive esophagitis are shown in Table 18.
Table 18: Life Table Analysis
| Omeprazole 20 mg once daily (n = 138) |
Omeprazole 20 mg 3 days per week (n = 137) |
Placebo (n = 131) |
|
| Percent in Endoscopic Remission at 6 Months | 701 | 34 | 11 |
| 1. (p < 0.01) omeprazole 20 mg once daily versus omeprazole 20 mg 3 consecutive days per week or placebo. | |||
In an international, multicenter, double-blind study, omeprazole 20 mg daily and 10 mg daily were compared to ranitidine 150 mg twice daily in patients with endoscopically confirmed healed esophagitis. Table 19 provides the results of this study for maintenance of healing of EE.
Table 19: Life Table Analysis
| Omeprazole 20 mg once daily (n = 131) |
Omeprazole 10 mg once daily (n = 133) |
Ranitidine 150 mg twice daily (n = 128) |
|
| Percent in Endoscopic Remission at 12 Months | 771 | 582 | 46 |
| 1. (p = 0.01) omeprazole 20 mg once daily versus omeprazole 10 mg once daily or Ranitidine. 2. (p = 0.03) omeprazole 10 mg once daily versus Ranitidine. |
|||
In patients who initially had grades 3 or 4 erosive esophagitis, for maintenance after healing 20 mg daily of omeprazole was effective, while 10 mg did not demonstrate effectiveness.
A double-blind, multicenter, randomized, non-inferiority clinical trial was conducted to compare ZEGERID oral suspension and intravenous cimetidine for the reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients (mean APACHE II score = 23.7). The primary endpoint was significant upper GI bleeding defined as bright red blood which did not clear after adjustment of the nasogastric tube and a 5 to 10 minute lavage, or persistent Gastroccult positive coffee grounds for 8 consecutive hours which did not clear with 100 mL lavage. ZEGERID oral suspension was administered as 40 mg (two doses administered 6 to 8 hours apart on the first day via orogastric or nasogastric tube, followed by 40 mg once daily thereafter) and intravenous cimetidine (300 mg bolus, followed by 50 to 100 mg/hr continuously thereafter) for up to 14 days (mean = 6.8 days). A total of 359 patients were studied, age range 16 to 91 (mean = 56 years), 58.5% were males, and 64% were Caucasians. The results of the study showed that ZEGERID oral suspension was non-inferior to intravenous cimetidine, 7/178 (3.9%) patients in the ZEGERID group vs. 10/181 (5.5%) patients in the cimetidine group experienced clinically significant upper GI bleeding.
ZEGERID®
(ze-ger-id)
(omeprazole and sodium bicarbonate)
for oral suspension and capsules, for oral use
What is the most important information I should know about ZEGERID?
ZEGERID may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.
ZEGERID can cause serious side effects, including:
Talk to your doctor about your risk of these serious side effects.
ZEGERID can have other serious side effects. See “What are the possible side effects of ZEGERID?”
What is ZEGERID?
A prescription medicine called a proton pump inhibitor (PPI) used to reduce the amount of acid in your stomach. ZEGERID for oral suspension and ZEGERID capsules is used in adults for:
ZEGERID for oral suspension is used:
It is not known if ZEGERID is safe and effective in children.
Do not take ZEGERID if you are:
Before taking ZEGERID, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Especially tell your doctor if you take:
Ask your doctor or pharmacist for a list of these medicines, if you are not sure. Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I take ZEGERID?
What are the possible side effects of ZEGERID?
ZEGERID can cause serious side effects, including:
The most common side effects of ZEGERID include:
These are not all the possible side effects of ZEGERID. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ZEGERID?
Keep ZEGERID and all medicines out of the reach of children.
General information about the safe and effective use of ZEGERID.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ZEGERID for any condition for which it was not prescribed. Do not give ZEGERID to other people, even if they have the same symptoms that you have. It may harm them. You can also ask your doctor or pharmacist for information about ZEGERID that is written for health professionals.
What are the ingredients in ZEGERID?
Active ingredients: omeprazole and sodium bicarbonate
Inactive ingredients in ZEGERID for oral suspension: xylitol, sucrose, sucralose, xanthan gum, and flavorings.
Inactive ingredients in ZEGERID capsules, for oral use: croscarmellose sodium and sodium stearyl fumarate.
INSTRUCTIONS FOR USE
ZEGERID®
(ze-ger-id)
(omeprazole and sodium bicarbonate)
for oral suspension
Taking ZEGERID for oral suspension:
Important: ZEGERID should be taken on an empty stomach at least 1 hour before a meal.
Giving ZEGERID for oral suspension with water through a nasogastric (NG) tube or orogastric (OG) tube:
Important: For patients receiving ZEGERID through a NG tube or OG tube, enteral feeding should be stopped approximately 3 hours before giving ZEGERID. You should wait at least 1 hour after giving ZEGERID before you start enteral feeding again.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
